NCT00476476View on ClinicalTrials.gov

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Squamous Cell Carcinoma
Interventions
DRUG

Erlotinib

Orally every day for about 4-6 weeks

Trial Locations (4)

02115

Beth Israel Deaconess Medical Center, Boston

02214

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

02905

Women and Infants Hospital of Rhode Island, Providence

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Women and Infants Hospital of Rhode Island

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00476476 - Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar | Biotech Hunter | Biotech Hunter